Madrigal Pharmaceuticals, Inc.

421.60-7.58 (-1.77%)

Oct 29, 4:00:01 PM EDT · NasdaqGS · MDGL · USD

Upcoming Earnings

Report date

Nov 4, 2025 (in 5 days)

Key Stats

Market Cap

9.40B

P/E (TTM)

Basic EPS (TTM)

-12.65

Dividend Yield

Recent Filings

10-Q

8/5/25Aug 5, 2025

8-K

8/5/25Aug 5, 2025

8-K

7/30/25Jul 30, 2025

8-K

7/22/25Jul 22, 2025

8-K

6/20/25Jun 20, 2025

About

Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania.

CEO

Mr. William J. Sibold

IPO

2/6/2007

Website

https://www.madrigalpharma.com

Employees

528

Sector

Healthcare

Industry

Biotechnology